当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Flagellin enhances the immunoprotection of formalin-inactivated Edwardsiella tarda vaccine in turbot.

Flagellin enhances the immunoprotection of formalin-inactivated Edwardsiella tarda vaccine in turbot.

Abstract：

:Edwardsiella tarda is an important fish pathogen that causes extensive losses in farmed fish around the world. Various types of vaccines have been developed against E. tarda infection, such as inactivated vaccine, live attenuated vaccine and subunit vaccine. However, inactivated vaccine exhibits poor immune protection against edwardsiellosis in some reports. In this study, we aimed to evaluate the protective effect of formalin-killed cells (FKC) against E. tarda with flagellin, FlgD, as an adjuvant in turbot. As a result, the relative percent survival (RPS) of turbot vaccinated with FKC reached 70% in the presence of FlgD adjuvant. Moreover, specific serum antibodies reached the highest level at 3weeks post vaccination. Furthermore, the transcription of some immune response-related genes, such as MHC-I, IgM, IL-1β, TCR, and TNFα were up-regulated in turbot after vaccination, indicating that both humoral and cellular immune responses were induced by this vaccine. In summary, flagellin can enhance immunoprotection of the formalin-inactivated E. tarda vaccine, which can be used as a potential adjuvant in fish vaccine.

journal_name

Vaccine

journal_title

Vaccine

authors

Liu X,Zhang H,Jiao C,Liu Q,Zhang Y,Xiao J

doi

10.1016/j.vaccine.2016.11.031

subject

Has Abstract

pub_date

2017-01-05 00:00:00

pages

369-374

issue

2

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(16)31078-7

journal_volume

35

pub_type

杂志文章

相关文献

VACCINE文献大全
  • The antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens.

    abstract：:In this study we have investigated the immunogenicity and antigenicity of synthetic immunocontraceptive vaccine candidates containing T- and B-cell epitopes arranged in different geometries. Two epitopes were selected, a B-cell epitope from fox sperm lactate dehydrogenase C(4) and a B-cell epitope from murine zona pel...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00255-8

    authors： Sadler K,Bird PH,Brown LE,Jackson DC

    更新日期：1999-10-14 00:00:00

  • Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.

    abstract：:The use of viral vectors in heterologous prime-boost regimens to induce potent T cell responses in addition to humoral immunity is a promising vaccination strategy in the fight against malaria. We conducted an open-label, first-in-human, controlled Phase I study evaluating the safety and immunogenicity of Matrix-M adj...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.09.028

    authors： Venkatraman N,Anagnostou N,Bliss C,Bowyer G,Wright D,Lövgren-Bengtsson K,Roberts R,Poulton I,Lawrie A,Ewer K,V S Hill A

    更新日期：2017-10-27 00:00:00

  • Indicators to assess National Immunization Technical Advisory Groups (NITAGs).

    abstract：:A National Immunization Technical Advisory Group (NITAG) is an expert advisory committee that provides evidence-based recommendations to the Ministry of Health (MoH) to guide immunization programs and policies. The World Health Organization (WHO), the Initiative for Supporting National Independent Immunization and Vac...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.01.047

    authors： Blau J,Sadr-Azodi N,Clementz M,Abeysinghe N,Cakmak N,Duclos P,Janusz C,Jauregui B,Mihigo R,Mosina L,Takashima Y,Senouci K

    更新日期：2013-05-28 00:00:00

  • Scale-up for bulk production of vaccine against meningococcal disease.

    abstract：:At the Netherlands Vaccine Institute (NVI) a vaccine against Neisseria meningitidis serogroup B organisms based on different porA subtypes contained in outer membrane vesicles (OMVs) is in advanced stage of development and will be evaluated in clinical trial studies in the near future. In order to meet the expected de...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.06.008

    authors： Baart GJ,de Jong G,Philippi M,van't Riet K,van der Pol LA,Beuvery EC,Tramper J,Martens DE

    更新日期：2007-08-21 00:00:00

  • Humoral and cellular immunity induced by antigens adjuvanted with colloidal iron hydroxide.

    abstract：:The immunopotentiating activities of colloidal iron hydroxide, a novel, experimental mineral adjuvant, and of aluminium hydroxide. the licensed adjuvant for human vaccines, were compared. Our studies revealed that colloidal iron hydroxide and aluminium hydroxide behaved comparably with respect to supporting induction ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00201-1

    authors： Leibl H,Tomasits R,Brühl P,Kerschbaum A,Eibl MM,Mannhalter JW

    更新日期：1999-03-05 00:00:00

  • A randomised vaccine field trial in Kenya demonstrates protection against wildebeest-associated malignant catarrhal fever in cattle.

    abstract：:Wildebeest-associated malignant catarrhal fever (WA-MCF), a fatal disease of cattle caused by alcelaphine herpesvirus 1 (AlHV-1), is one of the most important seasonal diseases of cattle in wildebeest endemic areas, with annual incidence reaching 10%. Here we report efficacy of over 80% for a vaccine based on the atte...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.08.040

    authors： Cook E,Russell G,Grant D,Mutisya C,Omoto L,Dobson E,Lankester F,Nene V

    更新日期：2019-09-20 00:00:00

  • Plant heat shock protein 90 as carrier-adjuvant for immunization against a reporter antigen.

    abstract：:Here, we evaluated the modulation of the immune response induced by Hsp90 of Nicotiana benthamiana (NbHsp90.3) against the Maltose Binding Protein (MBP) as a reporter antigen. Equimolar quantities of recombinant proteins were administered in mice as follows: MBP alone (MBP group), a mixture of MBP and rNbHsp90.3 (MBP+...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.09.047

    authors： Corigliano MG,Fenoy I,Sander V,Maglioco A,Goldman A,Clemente M

    更新日期：2013-12-02 00:00:00

  • Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.

    abstract：:The humoral response to synthetic peptide vaccines against Semliki Forest virus (SFV) in H-2d BALB/c mice was investigated with the enzyme linked immunosorbent assay and the pepscan technique. The peptide vaccines consisted of amino acid sequences 240-255 (B) and 137-151 (T) of the E2 membrane protein of SFV colinearl...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00038-3

    authors： Fernández IM,Harmsen M,Benaissa-Trouw BJ,Stuij I,Puyk W,Meloen RH,Snippe H,Kraaijeveld CA

    更新日期：1998-10-01 00:00:00

  • Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.

    abstract：:In this study, West Nile virus (WNV) envelope (rE) protein and its domain III (rDIII) were efficiently expressed in a cost-effective system based on insect larvae as non-fermentative living biofactories. Mice immunized with the partially purified rE or rDIII elicited high antibodies titers that neutralized viral infec...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.12.081

    authors： Alonso-Padilla J,de Oya NJ,Blázquez AB,Escribano-Romero E,Escribano JM,Saiz JC

    更新日期：2011-02-17 00:00:00

  • Past, present and future of HIV vaccine trials in developing countries.

    abstract：:A safe, effective and accessible preventive vaccine is our best long-term hope for the control of the HIV/AIDS pandemic. The first phase I trial of an HIV vaccine was conducted in the US in 1987. Since then, >30 candidate vaccines have been tested in over 60 phase I/II clinical trials, involving >8000 healthy human vo...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/s0264-410x(02)00062-2

    authors： Esparza J,Osmanov S,Pattou-Markovic C,Touré C,Chang ML,Nixon S

    更新日期：2002-05-06 00:00:00

  • Detection of measles vaccine in the throat of a vaccinated child.

    abstract：:Measles vaccine is widely used, most often in association with mumps and rubella vaccines. We report here the case of a child presenting with fever 8 days after vaccination with a measles-mumps-rubella vaccine. Measles virus was isolated in a throat swab taken 4 days after fever onset. This virus was then further gene...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00495-9

    authors： Morfin F,Beguin A,Lina B,Thouvenot D

    更新日期：2002-02-22 00:00:00

  • Confounder adjustment in vaccine safety studies: comparing three offset terms for case-centered approach.

    abstract：:The case-centered approach (CCA) can be useful in vaccine safety studies to adjust for time varying confounders, especially seasonality. The method compares the observed odds of vaccination in the time interval prior to the event with the expected odds of vaccination during this interval. The log of the expected odds ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.07.064

    authors： Qian L,Tseng HF,Sy LS,Jacobsen SJ

    更新日期：2013-01-02 00:00:00

  • The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice.

    abstract：:We have previously described the generation of HIV-1 V3-specific cytotoxic T-lymphocytes (CTL) responses in BALB/c (H-2d) mice following immunization with Ty-virus-like particles carrying the V3 loop of gp120 (V3-VLPs) without adjuvant. In this study the effects of various adjuvants on CTL induction by V3-VLPs was exa...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(96)00010-2

    authors： Harris SJ,Woodrow SA,Gearing AJ,Adams SE,Kingsman AJ,Layton GT

    更新日期：1996-07-01 00:00:00

  • In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability.

    abstract：:Class I molecules are conformationally sensitive to peptide binding, prolonging the complex's half-life on the surface of the cell. By making a series of H2-Kb anchor motif amino acid point substitutions in the ovalbumin 257-264 octamer, we were able to analyse subtle changes in peptide binding, Kb stabilization and i...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(95)93320-9

    authors： Lipford GB,Bauer S,Wagner H,Heeg K

    更新日期：1995-02-01 00:00:00

  • Cost of plasma-derived hepatitis B vaccine production.

    abstract：:It is generally accepted that the introduction of hepatitis B vaccine to national programmes of immunization in developing countries is desirable, but it has so far been constrained by the high cost of the vaccine. To determine the potential minimal costs of the vaccine, a study has been carried out of the production ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(90)90101-q

    authors： Mahoney RT

    更新日期：1990-08-01 00:00:00

  • Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques.

    abstract：:The human adenovirus type 19a/64 (hAd19a) is a rare serotype in the human population that transduces human dendritic cells (DCs) and human muscle cells more efficiently than the well-characterized human adenovirus type 5 (hAd5). To further characterize the potential of this vector as a vaccine we designed replication ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.07.075

    authors： Ragonnaud E,Schroedel S,Mariya S,Iskandriati D,Pamungkas J,Fougeroux C,Daradoumis J,Thomsen AR,Neukirch L,Ruzsics Z,Salomon M,Thirion C,Holst PJ

    更新日期：2018-10-01 00:00:00

  • Methodological challenges in measuring vaccine effectiveness using population cohorts in low resource settings.

    abstract：:Post-licensure real world evaluation of vaccine implementation is important for establishing evidence of vaccine effectiveness (VE) and programme impact, including indirect effects. Large cohort studies offer an important epidemiological approach for evaluating VE, but have inherent methodological challenges. Since Ma...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2015.07.062

    authors： King C,Beard J,Crampin AC,Costello A,Mwansambo C,Cunliffe NA,Heyderman RS,French N,Bar-Zeev N,VacSurv Consortium.

    更新日期：2015-09-11 00:00:00

  • Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.

    abstract：:For middle and low-income countries, the cost of HPV vaccines remains challenging. We conducted an open-label nonrandomized clinical trial evaluating immune response to the HPV-16/18 AS04-adjuvanted vaccine administered on a standard (months (M) 0-1-6) versus extended schedule (M 0-6-60) at 7, 21, 60, 72 and 120 month...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.vaccine.2013.11.059

    authors： Lazcano-Ponce E,Stanley M,Muñoz N,Torres L,Cruz-Valdez A,Salmerón J,Rojas R,Herrero R,Hernández-Ávila M

    更新日期：2014-02-03 00:00:00

  • Novel use of a N2-specific enzyme-linked immunosorbent assay for differentiation of infected from vaccinated animals (DIVA)-based identification of avian influenza.

    abstract：:Proper vaccination with validated companion differentiation of infected from vaccinated animals (DIVA) tests using a vaccine containing a heterologous neuraminidase to the field virus can be effective to control avian influenza (AI). However, indirect immunofluorescent assay, the only field validated DIVA test, has li...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.03.065

    authors： Kwon JS,Kim MC,Jeong OM,Kang HM,Song CS,Kwon JH,Lee YJ

    更新日期：2009-05-21 00:00:00

  • Estimated acceptance of HPV vaccination among Italian women aged 18-26 years.

    abstract：:In Italy vaccination against human papillomavirus (HPV) was introduced in the national immunization programme in 2007; the primary target for this vaccination is 11-year-old females, whereas vaccination for older age groups is still a matter of debate. This project was carried out in the period 2007-2009 to estimate t...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.08.079

    authors： Giambi C,Donati S,Declich S,Salmaso S,Ciofi Degli Atti ML,Alibrandi MP,Brezzi S,Carozzi F,Collina N,Franchi D,Lattanzi A,Meda M,Minna MC,Nannini R,Scherillo I,Bella A,PreGio Working Group.

    更新日期：2011-10-26 00:00:00

  • Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice.

    abstract：:Live-attenuated influenza vaccine (LAIV) delivered by large droplet intranasal spray is efficacious against infection. However, many of the large droplets are trapped in the external nares and do not reach the target nasal airway tissues. Smaller droplets might provide better distribution yielding similar protection w...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.01.059

    authors： Smith JH,Brooks P,Johnson S,Tompkins SM,Custer KM,Haas DL,Mair R,Papania M,Tripp RA

    更新日期：2011-03-21 00:00:00

  • Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.

    abstract：:In the United States, co-administration of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine and tetravalent meningococcal conjugate vaccine (MCV4) is recommended in adolescents. In this clinical study, 1341 adolescents received Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanof...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2010.11.057

    authors： Weston WM,Friedland LR,Wu X,Howe B

    更新日期：2011-01-29 00:00:00

  • Willingness to participate in Ebola viral disease vaccine trials and receive vaccination by health workers in a tertiary hospital in Ile-Ife, Southwest Nigeria.

    abstract：BACKGROUND:Ebola viral disease (EVD) epidemic need to be contained through means which include vaccination of susceptible population. Vaccination has eradicated major killer diseases. OBJECTIVE:The study determined the health workers willingness to participate in EVD vaccine clinical trials and receive EVD vaccine. M...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.10.004

    authors： Olowookere SA,Abioye-Kuteyi EA,Adekanle O

    更新日期：2016-11-11 00:00:00

  • Novel adjuvants derived from attenuated lipopolysaccharides and lipid As of purple non-sulfur photosynthetic bacteria.

    abstract：:Adjuvants are substances that enhance adaptive immune response to antigen. Development of a safe and effective immunostimulant adjuvant is essential for the efficacy of a vaccine to protect against infectious pathogens. Purple non-sulfur photosynthetic bacteria exhibited nontoxic natural lipid A variants that are dist...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.04.097

    authors： Masoud H

    更新日期：2019-06-06 00:00:00

  • Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.

    abstract：:Estimation of the full disease burden caused by Streptococcus pneumoniae is challenging due to the difficulties in assigning the aetiology especially in lower and upper respiratory infections. We estimated the pneumococcal disease burden by using the vaccine-preventable disease incidence (VPDI) of PHiD-CV10 vaccine (G...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2018.02.088

    authors： Palmu AA,Jokinen J,Nieminen H,Rinta-Kokko H,Ruokokoski E,Puumalainen T,Moreira M,Schuerman L,Borys D,Kilpi TM

    更新日期：2018-03-27 00:00:00

  • Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.

    abstract：:Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we co...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.02.075

    authors： Lapuente D,Ruzsics Z,Thirion C,Tenbusch M

    更新日期：2018-05-03 00:00:00

  • Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.

    abstract：INTRODUCTION:Vaccination of pregnant women protects both women and their newborns against some infectious diseases. Thailand implemented tetanus toxoid (TT) vaccination of pregnant women in 1977, which was replaced by tetanus-diphtheria toxoid (dT) vaccination in 2005. The tetanus-diphtheria-acellular pertussis (Tdap) ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.08.058

    authors： Wanlapakorn N,Maertens K,Thongmee T,Srimuan D,Thatsanathorn T,Van Damme P,Leuridan E,Poovorawan Y

    更新日期：2020-10-14 00:00:00

  • T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.

    abstract：:The aim was to develop T cell costimulatory molecules that are broadly applicable to augment anti-tumor immune responses upon application of a virus-modified tumor vaccine to cancer patients. We generated recombinant bispecific single-chain antibodies with one specificity directed against the CD3 or the CD28 antigen o...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.10.031

    authors： Haas C,Lulei M,Fournier P,Arnold A,Schirrmacher V

    更新日期：2005-03-31 00:00:00

  • The web and public confidence in MMR vaccination in Italy.

    abstract：:Measles, mumps and rubella (MMR) vaccination coverage in Italy has been decreasing starting from 2012 and, at the present, none of the Italian regions has achieved the goal of 95% coverage target. A decision of the Court of Justice of Rimini in March 2012 that awarded vaccine-injury compensation for a case of autism h...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.07.029

    authors： Aquino F,Donzelli G,De Franco E,Privitera G,Lopalco PL,Carducci A

    更新日期：2017-08-16 00:00:00

  • Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.

    abstract：:The carbohydrate moieties on HIV-1 envelope glycoprotein (Env) act as shields to mask conserved neutralizing epitopes, while the hyperimmunogenic variable regions are immunodominant in inducing non-neutralizing antibodies, representing the major challenge for using Env as a vaccine candidate to induce broadly neutrali...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.09.073

    authors： Fu M,Hu K,Hu H,Ni F,Du T,Shattock RJ,Hu Q

    更新日期：2019-12-03 00:00:00